Breakout Ventures, a venture capital firm specializing in scientific applications of artificial intelligence, has announced the closing of its $114 million Fund III. The fund will be used to invest in early-stage companies leveraging AI in biology, chemistry, and related scientific fields.
Fund Focus and Investment Strategy
Breakout Ventures intends to support at least 20 startups through this fund, with individual investments ranging from $500,000 to $5 million. The firm has already begun deploying capital, having made initial investments in three companies. According to Lindy Fishburne, Breakout’s managing director, the firm is specifically seeking companies that apply AI to overcome scientific complexities. This is a critical trend: AI is rapidly becoming essential for accelerating research and development in fields where traditional methods are slow and costly.
Firm Background and Growth
Founded in 2016 as a spinout from a Thiel Foundation grant program, Breakout Ventures has steadily increased its fund size. It previously raised $60 million in 2017 (Fund I) and $112.5 million in 2021 (Fund II), both focused on science-driven startups. The firm’s consistent fundraising success reflects the growing investor interest in the convergence of AI and scientific innovation. Raising Fund III took approximately 18 months, with contributions from limited partners including The Kraft Group, Pinegrove Venture Partners, and S-Cubed Capital.
Founder Profile and Investment Criteria
Breakout Ventures prioritizes founders with deep scientific expertise. Fishburne notes that these founders may come from academia (PhDs commercializing research) or industry (individuals with firsthand knowledge of market needs). The firm emphasizes “fit” – ensuring the founder is uniquely positioned to lead the specific company they are building. This focus on founder quality suggests Breakout believes execution is as important as the underlying technology.
Breakout Ventures’ strategy underscores the increasing role of AI in transforming scientific research and development. The firm’s growth and investor support demonstrate a strong belief in the potential for AI-driven breakthroughs across biology, chemistry, and beyond.
